Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability

Neurology

Volumn 57, Issue 12 SUPPL. 5, 2001, Pages

  Johnson, K P ^a   Brooks, B R ^a   Cohen, J A ^a   Ford, C C ^a   Goldstein, J ^a   Lisak, R P ^a   Myers, L W ^a   Panitch, H S ^a   Rose, J W ^a   Schiffer, R B ^a   Vollmer, T ^a   Weiner, L P ^a   Wolinsky, J S ^a  

^a UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLATIRAMER; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISABILITY; DOUBLE BLIND PROCEDURE; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REMISSION;

ADJUVANTS, IMMUNOLOGIC; DISABILITY EVALUATION; HISTORY, 20TH CENTURY; HUMANS; INJECTIONS, SUBCUTANEOUS; LONG-TERM CARE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PEPTIDES; RANDOMIZED CONTROLLED TRIALS;

EID: 0035956509     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Experimental models of human autoimmune disease: Overview and prototypes
2. The autoimmune reactivity to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis is potentially pathogenic: Effect of copolymer 1 on MOG-induced disease
3. Effect of cyclophosphamide on suppressor cell activity in mice unresponsive to EAE
4. Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells - Specificity and promiscuity
5. A pilot trial of copolymer 1 in exacerbating- remitting multiple sclerosis
6. A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis
7. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, doubleblind, placebo-controlled trial
8. Copolymer 1: Multicenter multiple sclerosis trial extension shows improved effects on relapse rate and disability
9. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
10. Non-parametric estimation from incomplete observations
11. Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial
12. The natural history of multiple sclerosis: A geographically based study. 2. Predictive value of the early clinical course
13. Clinical scales for multiple sclerosis
14. Design strategies in multiple sclerosis clinical trials
15. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: Experience during the first three years
16. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis
17. Antibodies to copolymer 1 do not interfere with its clinical effect
18. 2
19. Antibodies to copolymer 1 do not interfere with its therapeutic effect